Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial

OBJECTIVE: To estimate the incremental cost-effectiveness of infliximab versus conventional combination treatment over 21 months in patients with methotrexate-refractory early rheumatoid arthritis. METHODS: In this multicentre, two-arm, parallel, randomised, active-controlled, open-label trial, rheu...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Ann Rheum Dis
Main Authors: Eriksson, Jonas K, Karlsson, Johan A, Bratt, Johan, Petersson, Ingemar F, van Vollenhoven, Ronald F, Ernestam, Sofia, Geborek, Pierre, Neovius, Martin
Format: Artigo
Jezik:Inglês
Izdano: BMJ Publishing Group 2015
Teme:
Clinical and Epidemiological Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4431324/
https://ncbi.nlm.nih.gov/pubmed/24737786
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2013-205060
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki